Details

Autor(en) / Beteiligte

• BAROUCH, Dan H
• JINYAN LIU
• FORTHAL, Donald N
• OURMANOV, Ilnour
• HIRSCH, Vanessa M
• CARVILLE, Angela
• MANSFIELD, Keith G
• STABLEIN, Donald
• PAU, Maria G
• SCHUITEMAKER, Hanneke
• SADOFF, Jerald C
• BILLINGS, Erik A
• HUALIN LI
• RAO, Mangala
• ROBB, Merlin L
• KIM, Jerome H
• MAROVICH, Mary A
• GOUDSMIT, Jaap
• MICHAEL, Nelson L
• MAXFIELD, Lori F
• ABBINK, Peter
• LYNCH, Diana M
• JUSTIN IAMPIETRO, M
• SANMIGUEL, Adam
• SEAMAN, Michael S
• FERRARI, Guido

Titel

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Ist Teil von

• Nature (London), 2012-02, Vol.482 (7383), p.89-93

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2012

Link zum Volltext

Quelle

PBSC : Psychology and Behavioral Sciences Collection - Journals

Beschreibungen/Notizen

• Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have typically shown post-infection virological control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges. Here we demonstrate vaccine protection against acquisition of fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus monkeys. Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIV(SME543) Gag, Pol and Env antigens resulted in an 80% or greater reduction in the per-exposure probability of infection against repetitive, intrarectal SIV(MAC251) challenges in rhesus monkeys. Protection against acquisition of infection showed distinct immunological correlates compared with post-infection virological control and required the inclusion of Env in the vaccine regimen. These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys.